High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in N'Djamena, Chad

Antiretroviral drug resistance was evaluated in 88 adults infected with human immunodeficiency virus, most with subtype CRF11_cpx, who had received a first-line antiretroviral regimen for 6 months, in N'Djamena, Chad. A total of 47 patients (53%) had detectable viral load at month 6, and 56 (64...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2009-07, Vol.49 (1), p.155-159
Hauptverfasser:	Koyalta, Donato, Charpentier, Charlotte, Beassamda, Jatibi, Rey, Elisabeth, Si-Mohamed, Ali, Djemadji-Oudjeil, Noël, Bélec, Laurent
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Anti-HIV Agents - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiretroviral Therapy, Highly Active Antiretrovirals Antiviral agents Antivirals Biological and medical sciences Chad Drug resistance Drug Resistance, Viral Drug therapy Genetic mutation Highly active antiretroviral therapy HIV HIV 1 HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects HIV-1 - isolation & purification HIV/AIDS Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Medical sciences Molecular Sequence Data Mutation Mutation, Missense Pharmacology. Drug treatments RNA, Viral - genetics Sequence Analysis, DNA Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral load Virology Viruses Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Antiretroviral drug resistance was evaluated in 88 adults infected with human immunodeficiency virus, most with subtype CRF11_cpx, who had received a first-line antiretroviral regimen for 6 months, in N'Djamena, Chad. A total of 47 patients (53%) had detectable viral load at month 6, and 56 (64%) had at least 1 antiretroviral resistance mutation observed.
ISSN:	1058-4838 1537-6591
DOI:	10.1086/599611